Skip to content

Study finds taking Haleon’s Centrum Silver daily may slow biological ageing

An analysis of the data from the COSMOS randomised trial provides early evidence that taking a daily Centrum Silver multivitamin may help support healthy ageing at the cellular level.

 A new peer-reviewed study published in Nature Medicine, a leading medical journal, shows that taking Haleon’s Centrum Silver may slow biological ageing in older adults.

The study looked at five DNA-based ‘epigenetic clocks’ to see how a daily multivitamin might influence healthy ageing in healthy older adults2. Compared to the placebo-only group, people in the multivitamin group had slowing in all five clocks, including statistically significant slowing seen in the two clocks that are predictive of mortality. The authors of this study, state that the changes equated to about four months less biological ageing over the course of two years.

The findings come from an analysis of data from the COcoa Supplement and Multivitamin Outcomes Study (COSMOS), a study designed to evaluate how taking a daily multivitamin may help support healthy ageing in healthy older adults.

With more than 40 years of nutrition research behind it, Centrum is the most clinically studied multivitamin in the world. These findings strengthen this scientific evidence base, marking a meaningful advance in the scientific rigour behind Haleon’s portfolio of category-leading brands. They also represent the first evidence from a large-scale, long-term randomised clinical trial indicating that a daily multivitamin may offer a safe, accessible and affordable option to support healthy ageing at the cellular level.

Carl Haney, chief research and development officer, Haleon, said: “These important new findings are a powerful example of how Haleon turns world-class science into real competitive advantage. It raises the bar on decades of clinical evidence behind Centrum, strengthening the credibility and trust our brands hold with consumers and healthcare professionals worldwide. It shows how the science behind our brands sets the standard and supports our growth strategy as we aim to reach one billion more consumers globally.”

Submit Your Press Release

Have news to share? Send us your press releases and announcements.

Send Press Release

Latest

Embecta to acquire Owen Mumford

Embecta to acquire Owen Mumford

Move will position embecta to participate in the rapidly expanding market for drug-delivery devices supporting generic and branded therapies and accelerate transformation into a broad‑based medical supplies company.